Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer

N C Levitt, Trivadi S. Ganesan(Churchill Hospital), C.B. Echeta(Churchill Hospital), David Propper(St Bartholomew's Hospital), S Joel(St Bartholomew's Hospital), Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Robert te Poele(St Bartholomew's Hospital), Ian D. Hickson(University of Copenhagen), Elizabeth Flanagan(Churchill Hospital), S L Davies(At Bristol), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
British Journal of Cancer
June 14, 2005
10.1038/sj.bjc.6602657
Cited by 7

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
|The Lancet Oncology|2020|351